Institute scientists are optimizing data for more precise cancer diagnosis, treatment
Mar. 27—David Guinovart, PhD, and Eric Rahrmann, PhD, assistant professors at The Hormel Institute, University of Minnesota, are the recipients of a two-year, $100,000 Data Science Initiative (DSI) Seed Grant from the University of Minnesota.
Their funded project, MOOBI: Multi-Omics Optimization-Based Integration for Enhanced Cancer Research Datasets, aims to tackle key challenges in integrating multi-omics data for more precise breast cancer diagnosis and therapeutic targets.
Multi-omics is a biological analysis approach that makes use of multiple types of datasets. In this project, Guinovart and team are leveraging data made publicly available from The Cancer Genome Atlas (TCGA). They aim to develop a new, integrated dataset with the ultimate goal of enhancing breast cancer subtype classifications and identifying biomarkers for diagnosis and therapeutic targets. This means patients could have a higher likelihood of being matched with the right treatment options for the right cancer as early as possible.
With his background in applied mathematics, Guinovart sought Rahrmann's expertise in cancer biology and metastasis for this interdisciplinary collaboration.
"The way we see this collaboration is an integrative process: we develop an idea, Eric will offer his ideas, and we will adjust as needed. It keeps the model not only accurate, but also fresh," Guinovart said. "In this particular case, we are trying to add more information to this already available data, developing a model that can respond to real-life problems more effectively. I think this could be used for other opportunities, but we will also have a clean dataset that has been validated at another level. We will also be able to share this ready-to-use data to fit other models, ideas, or research."
With Guinovart an applied mathematician and Rahrmann an expert in developmental biology, cancer biology and metastasis, this endeavor is a collaboration that helps keep the ideas considered and models developed accurate and fresh.
"Too often, we only look at the tip of the iceberg and ignore the rest of the data. Essentially, we're going back with these new, innovative approaches to revisit old questions and ultimately identify new biomarkers and therapeutic targets," Rahrmann said.
The project also holds potential for broader applications in the future. Rahrmann said that the data may be helpful in identifying transition phases of cancer toward hybrid cancer types at critical times of disease progression.
The TCGA has a treasure trove of data — 2.5 petabytes, in fact, or 2.5 million gigabytes — that has been gathered over decades of research. With so much information at hand, projects like this can find new connections and applications that have yet to be discovered.
Once the research team has its refined, well-structured data, they will feed that data to machine learning models that use multiple parameters for optimized classification to minimize false positives in cancer diagnosis as much as possible.
Post-Doctoral Associate Mohammed Qaraad, PhD, and Senior Scientist Kayum Alam, PhD, are also contributing to the project.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
2 days ago
- Associated Press
Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection
~ PF614-MPAR Moving to Next Stage of Development, Finalizing Drug Formulation ~ ~ Funds Accelerate Path Towards Commercialization ~ SAN DIEGO, CA / ACCESS Newswire / June 4, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ('Ensysce' or the 'Company'), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced it was awarded the second $5.3 million installment of a $15 million, three-year grant from the National Institute on Drug Abuse (NIDA)1. This continued support will accelerate the clinical and non-clinical development of PF614-MPAR, a next-generation opioid designed to offer powerful pain relief while dramatically reducing the risk of overdose. PF614-MPAR, which has earned the FDA's prestigious Breakthrough Therapy designation, is uniquely engineered using Ensysce's proprietary TAAP™ (Trypsin-Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance) technologies. These platforms enable PF614-MPAR to maintain therapeutic efficacy while offering built-in overdose protection - even when doses exceed prescribed amounts, whether accidentally or intentionally. The first year of NIDA funding, together with outside capital raised, enabled a series of promising clinical studies that validated PF614-MPAR's ability to prevent overdose. This next phase of funding which began on June 1, 2025, will focus on optimizing the final drug formulation, undertaking further clinical evaluation while preparing to move to commercialization. Ensysce plans to engage with the FDA in the coming months to align on full development plans based on the robust data generated to date. Dr. Lynn Kirkpatrick, CEO of Ensysce, commented, 'Our initial clinical results confirm what we set out to achieve - a safer opioid that can offer what we believe is real protection in overdose scenarios. PF614-MPAR is the only opioid product to receive FDA Breakthrough Therapy status, a testament to its potential impact. NIDA's continued support is a powerful endorsement of our mission to deliver innovative, life-saving solutions for pain management. With these additional funds, we're accelerating toward commercialization and look forward to working closely with the FDA on our next steps.' 1The research is supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number UO1DA059791. About Ensysce Biosciences Ensysce Biosciences is a clinical stage company with a goal of disrupting the analgesic landscape by introducing a new class of highly novel opioids for the treatment of severe pain. Leveraging its Trypsin-Activated Abuse Protection (TAAPTM) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. For more information, please visit Forward-Looking Statements Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as 'may,' 'intends,' 'can,' 'might,' 'will,' 'expect,' 'plan,' 'possible,' 'believe' and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce's management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce's business is subject to additional risks and uncertainties, including among others, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce's product candidates; the availability or commercial potential of product candidates; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from our fundraising; and Ensysce's and its partners' ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce's most recent quarterly report on Form 10-Q and current reports on Form 8-K, which are available, free of charge, at the SEC's website at Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law. Ensysce Biosciences Company Contact: Lynn Kirkpatrick, Ph.D. Chief Executive Officer (858) 263-4196 Ensysce Biosciences Investor Relations Contact: Shannon Devine MZ North America Main: 203-741-8811 [email protected] SOURCE: Ensysce Biosciences press release
CBS News
3 days ago
- CBS News
3 injured in multi-vehicle crash in Beach Park, Illinois
Three people were injured in a multi-vehicle crash Tuesday morning in Chicago's far northern suburbs. Lake County Sheriff's police said, around 8 a.m., a GMC Acadia was headed north on Sheridan Road when it struck the stop arm of a school bus which was stopped near Mawman Avenue in Beach Park, Illinois. The GMC kept heading north, and sideswiped a Ford Focus, pushing it into a utility pole. The GMC then hit a Chevrolet Colorado pickup truck and a Ford Flex SUV in the oncoming lanes of Sheridan Road. Police said it's possible the driver of the GMC, a 74-year-old man from Zion, Illinois, suffered a medical emergency before the crash. He was taken to the hospital in critical condition. Neither the driver nor the two children on the school bus were injured. The driver of the Ford Focus and the driver of the Chevrolet Colorado were taken to the hospital in serious condition, but police said their injuries were not life-threatening. The driver of the Ford Flex was not injured. The cause of the crash was under investigation Tuesday afternoon.
Yahoo
4 days ago
- Yahoo
Explainer-How flesh-eating screwworms in cattle could raise US beef prices
By Heather Schlitz CHICAGO (Reuters) - New World Screwworm, a devastating parasite that eats cattle and other wild animals alive, is traveling north from Central America to Mexico and has crept past biological barriers that kept the pest contained for decades, experts said. Washington halted cattle imports from Mexico in May, citing the insect's spread further into Mexico, about 700 miles from the Texas border. With the U.S. cattle herd already at a multi-decade low, the closure could further elevate record-high beef prices by keeping more calves out of the U.S. cattle supply. What is New World Screwworm? Screwworms are parasitic flies whose females lay eggs in wounds on any warm-blooded animal. Livestock and wild animals are usually the victims. Once the eggs hatch, hundreds of screwworm larvae use their sharp mouths to burrow through living flesh -- feeding, enlarging the wound and eventually killing their host if left untreated. When screwworms infect a cow, a tiny scrape, a recent brand or a healing ear tag can quickly become a gaping wound, carpeted with wriggling maggots that put the entire herd at risk of infestation. Screwworms were eradicated from the U.S. in the 1960s when researchers began releasing massive numbers of sterilized male screwworm flies who mate with wild female screwworms to produce infertile eggs. Why does this matter to U.S. consumers? The U.S. typically imports over a million cattle from Mexico every year. The import suspension will likely contribute to rising beef prices by tightening the supply of beef cattle, which dwindled after drought forced ranchers to slash herds. U.S. beef prices likely also got a boost from a separate import suspension from Mexico over screwworms that lasted from November to February, experts said, and upward pressure on prices should persist through summer grilling season. Mexican cattle are usually fed and fattened on U.S. farms for five to six months before slaughter, and a diminished slaughter rate can elevate beef prices. Though the fly is hundreds of miles away from the border, any outbreak in the U.S. would further tighten the cattle supply and put other livestock and household pets at risk. Screwworms will even feed on humans if they can, said Dr. Timothy Goldsmith, a veterinary medicine professor at the University of Minnesota. Homeless people would be especially vulnerable to infestation because they sleep outside and have less access to hygiene products and medical care, Goldsmith said. What is being done to control the outbreak? A factory designed to breed and sterilize screwworms in Panama is releasing 100 million sterile flies every week, but experts say more factories need to come online quickly to choke off the fly's spread north. Screwworms cannot fly more than 12 miles on their own, but they can cover large distances while burrowed inside their hosts, said Sonja Swiger, entomologist at Texas A&M University. The flies have already passed through the narrowest stretches of land in Panama and Mexico, meaning exponentially more sterile flies need to be released to control the outbreak. On Tuesday, the U.S. Department of Agriculture announced it would invest $21 million to convert a fruit fly factory in Mexico to produce sterile screwworms. The agency said the border will likely re-open to cattle imports by the end of the year. How could this impact American cattle ranchers? The USDA estimated a screwworm outbreak would cost the Texas economy $1.8 billion in livestock deaths, labor costs and medication expenses. After decades of eradication, most cattle ranchers no longer have the experience or tools to diagnose and treat screwworm. Infestations can be cured, but treatment involves removing hundreds of larvae and thoroughly disinfecting wounds, a time-consuming, pricey and labor-intensive process. 'This is a pest we don't want back. This is a bad thing," said David Anderson, livestock economist at Texas A&M University. "I can't imagine having to deal with that. It's gross."
